Background: Lung cancer is the leading cause of cancer death. Platelet-related indictors, including platelet count, plateletcrit, mean platelet volume, and platelet distribution width, not only associate with morphology and functions of platelet but also correlate with tumor development and metastasis. In the present study, we investigated the values of platelet-related indictors in the prognosis evaluation of resectable lung cancers. Methods: In total, 101 patients with resectable lung cancer were recruited in this study. Patients were divided into 2 groups according to the median pretreatment values. To evaluate the individual value changes after treatment, we introduced the concept of post-/pretreatment ratio ( 1 indicated value was not increased after treatment, while >1 suggested increased value). Results: The high pretreatment platelet count level was correlated with larger tumor size. High pretreatment plateletcrit level was associated with more lymph nodes metastasis. Patients with high pretreatment plateletcrit level had worse overall survival, whereas pretreatment platelet count, mean platelet volume, and platelet distribution width levels were not correlated with outcomes. Surgery had no impact on the values of platelet count, plateletcrit, mean platelet volume, or platelet distribution width. Adjuvant chemotherapy significantly decreased the values of platelet count and plateletcrit, whereas it had no effect on the values of mean platelet volume or platelet distribution width. Whole course of treatment (surgery combined with adjuvant chemotherapy) significantly decreased the values of platelet count and platelet distribution width, whereas it had no effect on the values of plateletcrit or mean platelet volume. Post-/pretreatment platelet count, plateletcrit, mean platelet volume, and platelet distribution width ratios were not correlated with outcomes. Univariate analyses demonstrated that American Joint Committee on Cancer stage and pretreatment plateletcrit level were significant risk factors for prognosis. Cox regression analysis revealed that no factor independently associated with worse survival. Conclusion: Pretreatment plateletcrit level could be a potential prognostic factor in resectable lung cancers.
Introduction
Lung cancer is the second most commonly diagnosed cancer but is the leading cause of cancer-related death. 1 Researchers have indicated that lung cancers take up nearly 27% of total cancer death. 1 There are 2 histological types of lung cancer: small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC). Approximately 80% lung cancers are NSCLC, which includes adenocarcinoma, squamous cell carcinoma and large-cell carcinoma. About 90% occurrence of NSCLC are linked with smoking. 2 Surgical resection is the major choice for patients at early stages. 3 Platelet-related indicators include platelet count (PLT), plateletcrit (PCT), mean platelet volume (MPV), and platelet distribution width (PDW). In recent years, platelet has been testified to participate in the development and metastasis of cancer. [4] [5] [6] Platelet-related indicators are associated with multiple tumor prognosis, including rectal cancer, 7, 8 pancreatic cancer, 9 gastric cancer, 10 and so on. Previous studies have found that platelet-related indicators in patients with lung cancer are more variable than those in the control group. 11 Maraz and colleagues proved that in patients with resectable lung cancer, there was a negative correlation between high PLTs and overall survival (OS). 12 Zhang and Ran demonstrated that elevated PLT denotes a poor prognosis in patients with lung cancer. 13 Previous studies have indicated that the number and activity of platelets are associated with variety of malignancies. 6 Plateletcrit provides more comprehensive data about total platelet mass because it is the combination of MPV and PLTs, where PCT ¼ PLT Â MPV/10. 7, 14 Mean platelet volume is a platelet volume index and is recognized as a hallmark of platelet activation. 10, 15 Platelet distribution width is a parameter of variation in platelet size. High PDW level can be a sign of activated platelet production. Elevated platelet release will lead to an increase in the average platelet size and consequently affects the PDW. 16 In our present study, we aimed to investigate whether platelet-related indicators could provide beneficial prognostic information for patients with resectable lung cancer and whether they have an impact on the patients' OS.
Materials and Methods

Participants and Inclusion Criteria
The study was conducted from March 2017 to August 2017 as a retrospective investigation of patients with resectable lung cancer who had been referred to the First Affiliated Hospital of Soochow University (Jiangsu, China) between January 2007 and May 2016. Approval for the study was granted by the Medical Ethics Committees of the First Affiliated Hospital of Soochow University. Clinical and pathological records of all the patients participating in the study were reviewed periodically. The inclusion criteria were as follows: (1) those with histologically or cytologically confirmed resectable lung cancer; (2) age 18 to 70 years; (3) Eastern Cooperative Oncology Group performance status score of 1; (4) those with a predicted survival of !6 months; (5) those who met the following laboratory criteria: white blood cells (WBCs) !4.0 Â 10 9 /L; absolute neutrophil count ! 2.0 Â 10 9 /L; PLT ! 100Â 10 9 /L. The inclusion criteria were as follows: the patient failed to complete adjuvant chemotherapy after surgery. Censored data defined as patients whose survival time exceeds the last followup time or lost after treatment.
After obtaining informed consent, a total of 101 patients with resectable lung cancer were recruited in the study. All cases were confirmed by surgery and pathology. Patient characteristics are detailed in Table 1 . The median age of the 101 patients was 60 years (range, 80-27 years), and 63 patients were males and 38 were females. The pathologic types were divided into NSCLC and SCLC. The staging of cancer was made according to tumor-nodulus-metastases classification and classified through the American Joint Committee on Cancer (AJCC) recommendations. The prognostic analyses were performed regarding OS.
Blood Samples
Peripheral venous blood (5-7 mL) was collected into a sterile EDTA tube. All blood samples were fasted and obtained between 6:30 and 7:30 AM in order to standardize the known impact of circulating hormones (circadian rhythm) on the number and subtype distribution of the various WBC indices. Hematological parameters were analyzed within 30 minutes after collection using a hematology analyzer (Sysmex XE-2100; Sysmex, Kobe, Japan). The patients were divided into 2 groups according to the median value of PLT, PCT, MPV, or PDW. The post-/pretreatment ratios were defined as the ratio of pretreatment platelet-related parameter values and the corresponding ones obtained after therapy.
Evaluation
Computed tomography scan was performed for the assessment of response every 2 months and evaluated according to the criteria of Response Evaluation Criteria in Solid Tumors 1.1. 
Follow-Up
Survival time generally means OS in oncology, which was measured from the date of diagnosis until death or last clinical evaluation. The prognostic analyses were performed regarding OS. Overall survival was defined as the time from the diagnosed date to death from any cause.
Statistical Analysis
All statistical analyses were performed using SPSS 19.0 software (Chicago, Illinois). For analysis of survival data, KaplanMeier curves were constructed, and statistical analysis was carried out using the log-rank test. The associations between blood parameters status and clinicopathologic features were explored by the w 2 tests. The relationship between changes in the blood parameters status and surgery or chemotherapy were assessed by the t tests. Cox regression analysis was used to identify the independent risk factors associated with resectable lung cancer using a backward elimination technique, which involves including all the independent variables into the equation and gradually eliminating the nonstatistical independent variables to derive a potentially suitable set of predictors. 17, 18, 19 All values of P < .05 were considered statistically significant.
Results
Pretreatment PCT Level Predicted Outcomes of Patients With Resectable Lung Cancer
The Kaplan-Meier plots were used to determine the effect of pretreatment PLT, PCT, MPV, and PDW status on OS ( Figure  1A-D) . The patients were divided into 2 groups according to the median value of PLT (low PLT, 219.000 Â 10 9 /L or high PLT >219.000 Â 10 Relationships between status of pretreatment platelet-related indicators and the outcomes. A, The OS according to PLT: pretreatment levels of PLT had no effects on OS. B, The OS according to PCT: higher pretreatment levels of PCT levels are associated with worse OS. C, The OS according to MPV: pretreatment levels of MPV had no effects on OS. D, The OS according to PDW: pretreatment levels of PDW had no effects on OS. *P < .05; **P < .01. MPV indicates mean platelet volume; OS, overall survival; PCT, plateletcrit; PDW, platelet distribution width; PLT, platelet count. (25.335-34.665 ) months in the low-PDW group (P ¼ .173). Thus, the patients whose PCT levels were higher before treatment had worse prognosis. However, pretreatment levels of PLT, MPV, or PDW had no effects on OS.
Effects of Surgery on the Values of Platelet-Related Indicators
The effects of surgery on the levels of platelet-related indicators were presented in Figure 2A The median value of PDW was 13.700% (13.080%-15.600%) before treatment and 12.510% (11.950%-14.450%) after treatment (P ¼ .011). Thus, whole course of treatment significantly decreased the values of PLT and PDW, whereas it had no obvious effect on the value of PCT or MPV.
Changes in PLT, PCT, MPV, and PDW Levels After Whole Course of Treatment Were not Correlated with the Outcomes of Patients With Resectable Lung Cancer
The Kaplan-Meier plots were used to determine the effect of changes of the PLT, PCT, MPV, and PDW status on OS ( Figure  5A-D (Table 2) . However, gender, age, pathologic type, tumor size, depth of invasion, lymphonodus metastasis, and post-/pretreatment other platelet-related indictors had no significance to the prognosis (Table 2 ). In Cox regression analysis, we found no factor was independently associated with worse survival. 
Discussion
Platelets play an integral role in the development and metastasis of cancer. 6, 20 Platelet parameters, including PCT, MPV and PDW, closely relate to the function and activation of platelets. 7, 14, 21, 22 Previous studies have confirmed that plateletrelated indicators were associated with prognosis of tumors. 7, 12, 23 Maraz and colleagues proved that there was a negative correlation between high PLTs (!400.00 Â 10 9 /L) and OS in patients with resectable lung cancer. 24 Once activated, platelets can bind to tumor cells via P-selectin which presents on the surface of platelets and bind to CD24 ligand. 25, 26 In addition, platelets facilitate tumor growth and metastasis through releasing proangiogenic and growth factors. 25 For instance, activated platelets promote metastasis by secreting lysophosphatidic acid (LPA), a lipid that has growth factor-like properties and plays a role in many cellular processes including cell proliferation, survival, migration, tumor cell invasion, and reversal of differentiation. 27 Furthermore, platelet is a primary source of vascular endothelial growth factor, a growth factor that increases vascular permeability, promotes extravasation, and is critical for angiogenesis. 28 Finally, tumor-derived platelets also predispose patients with cancer to thrombotic events. Venous thromboembolism and high PLTs are risk factors associated with poor prognosis in patients with cancer. 9, [29] [30] [31] In our present study, both surgery and adjuvant chemotherapy significantly reduced the level of PLT, although pretreatment level and post-/pretherapeutic ratio of PLT had no significant effects on OS.
Plateletcrit, which is the combination of 2 aspects including PLT and MPV, is the percentage of blood volume covered by platelets and is a relevant parameter to assess platelet status.
14, 22 Ozaksit et al proved that the value of PCT is higher in patients with epithelial ovarian cancer compared to the healthy controls. 32, 33 Besides, high PCT was associated with worse prognosis in patients with pancreatic adenocarcinoma who received intensity-modulated radiation therapy. 34 Interestingly, negative correlations were observed between the induced frequency of micronuclei and PCT in differentiated patients with thyroid cancer undergoing radioactive iodine ( 131 I) treatment following thyroid and lymph node surgery. Therefore, PCT may be used as a biomarker for diagnosis, prognosis, and radiosensitivity in certain cancers. 35 Oncel et al certified that the PCT values of patients with metastatic lung cancer were higher than those of patients without metastasis. While comparing to healthy controls, the value of PCT was lower. 36 In the present study, we found that the contribution of the downregulation of PCT could be mainly made by chemotherapy since surgery had no effect on PCT status. Moreover, patients with low pretreatment level of PCT had better outcomes. Univariate analyses demonstrated that high pretreatment PCT level was a significant risk factors for a poor prognosis. Although basing on changes in individual PCT levels, post-/pretherapeutic ratio of PCT had no significant effects on OS, low PCT level before treatment could be a favorable prognostic index.
Mean platelet volume, a common parameter of platelet size, could be used as an index of activated platelet. 21 Multiple investigators have reported that increased MPV could be detected in acute myocardial infarction, unstable angina, and stroke. [37] [38] [39] [40] In addition, this index is also investigated in a variety of malignant tumors. 22, 41, 42 According to the report from Baldane et al, the level of MPV in patients with thyroid cancer was significantly higher when compared to benign goiters or healthy controls. 43 Similar results have also been found in colorectal cancers. 23, 44, 45 Nevertheless, a research reported that MPV was higher in lung cancers at early stages (stage I-II) than healthy controls. 12 Previous studies have also pointed out that high MPV level is closely related to inflammatory response. [46] [47] [48] [49] As an inflammation marker, high MPV level is correlated with various malignant tumors, such as endometrial cancer, gastric cancer, and thyroid cancer. 7, 43, 50 Previous researches have demonstrated that several inflammatory factors, such as interleukin (IL) 1, IL-3 and IL-6 can promote the proliferation of macrophages and further lead to increased platelet level. 51, 52 Many tumor tissues can detect the elevated levels of IL-6, including lung cancer. 53 Thus, cancer-induced changes in MPV status could be due to response to inflammatory stimuli. However, in our present study, we found that neither surgery nor adjuvant chemotherapy could affect MPV level. Besides, pretreatment level and post-/pretherapeutic ratio of MPV had no significant effects on OS.
Previous investigations concerning PDW are controversial. In a study of Emel Kurtoglu, the PDW level significantly decreased in the patients with endometrial cancer compared to the healthy group. 7 However, Gunaldi and colleagues demonstrated that high PDW level is positively correlated with metastasis of gastric cancer. 54 Hirahara et al proved that PDW levels and prognosis of esophageal cancer had no statistically significant relationship. 16 In the present study, although treatment significantly decreased the value of PDW, pretreatment level, and post-/pretherapeutic ratio of PDW had no significant impact on OS. Relationship between changes in status of pretreatment platelet-related indicators and the outcomes. A, Changes in PLT levels upon treatment had no significant effects on OS. B, Changes in PCT levels upon treatment had no significant effects on OS. C, Changes in MPV levels upon treatment had no significant effects on OS. D, Changes in PDW levels upon treatment had no significant effects on OS. *P < .05; **P < .01. MPV indicates mean platelet volume; OS, overall survival; PCT, plateletcrit; PDW, platelet distribution width; PLT, platelet count.
In conclusion, our data showed that low PCT level before treatment had better OS in patients with resectable lung cancer. This noninvasive, simple, and low-cost biomarker may be a prognostic indicator. The limitations of our study may include its retrospective design, data coming from single center, and insufficiency of case number.
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